<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04312594</url>
  </required_header>
  <id_info>
    <org_study_id>ZGJAK005</org_study_id>
    <nct_id>NCT04312594</nct_id>
  </id_info>
  <brief_title>Jaktinib Dihydrochloride Monohydrate in Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind,Placebo-controlled,Phase 2 Trial of Jaktinib Dihydrochloride Monohydrate in Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Jaktinib Dihydrochloride Monohydrate for idiopathic pulmonary fibrosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase 2 study of Jaktinib Dihydrochloride Monohydrate, an oral inhibitor of JAK1 、JAK2
      and JAK3, is to assess efficacy and safety in patients with idiopathic pulmonary fibrosis.The
      study is a randomised,multicentre,double-blind,placebo-controlled,study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2020</start_date>
  <completion_date type="Anticipated">October 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in forced vital capacity (FVC) [ Time Frame: 24 weeks ]</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes in FVC from 24 weeks to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free time [ Time Frame: the onset of disease or death from any cause ]</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months</time_frame>
    <description>The time from a random date to the onset of disease or death from any cause;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-worsening survival time: [ Time Frame:the time from randomization to the first acute exacerbation ];</measure>
    <time_frame>from randomization to one month</time_frame>
    <description>acute aggravation events should meet all the following conditions: (1) acute exacerbation or aggravation of respiratory distress within 1 month;Chest CT showed new bilateral ground glass shadows or pulmonary interstitial fibrosis with pulmonary consolidation;(3) exclude heart failure, fluid retention and infection caused by acute dyspnea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>K-BILD Scale: absolute value of change from baseline [ Time Frame: 24 weeks ]</measure>
    <time_frame>24 weeks</time_frame>
    <description>absolute value of change from baseline at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mMRC Dyspnea scale：absolute value of change from baseline [ Time Frame: 24 weeks ]</measure>
    <time_frame>24 weeks</time_frame>
    <description>absolute value of change from baseline at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate: [ Time Frame: 6 months, 12 months, 24 months ]</measure>
    <time_frame>6 months, 12 months, 24 months</time_frame>
    <description>Survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The severity and incidence of all adverse events and adverse reactions[ Time Frame: within 28 days after the signing of the informed consent]</measure>
    <time_frame>within 28 days after the signing of the informed consent</time_frame>
    <description>The severity and incidence of all adverse events and adverse reactions</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Jaktinib Dihydrochloride Monohydrate 50mg and Basic treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and basic treatment(Acetylcysteine Effervescent Tablets 600mg TID) for each 24 weeks cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Jaktinib Dihydrochloride Monohydrate 75mg and Basic treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and basic treatment(Acetylcysteine Effervescent Tablets 600mg TID) for each 24 weeks cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Basic treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Mimic tablets of Jaktinib Dihydrochloride Monohydrate 50mg BID and 75mg BIDand basic treatment(Acetylcysteine Effervescent Tablets 600mg TID) for each 24 weeks cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and Acetylcysteine Effervescent Tablets</intervention_name>
    <description>after continuing to intolerance or progress in double blind treatment period for 24 weeks,for tolerance into open therapy period for evaluated by investigator</description>
    <arm_group_label>Jaktinib Dihydrochloride Monohydrate 50mg and Basic treatment</arm_group_label>
    <other_name>treatment drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and Acetylcysteine Effervescent Tablets</intervention_name>
    <description>after continuing to intolerance or progress in double blind treatment period for 24 weeks,for tolerance into open therapy period for evaluated by investigator</description>
    <arm_group_label>Jaktinib Dihydrochloride Monohydrate 75mg and Basic treatment</arm_group_label>
    <other_name>treatment drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet and Acetylcysteine Effervescent Tablets</intervention_name>
    <description>after continuing to intolerance or progress in double blind treatment period for 24 weeks,for tolerance into open therapy period for evaluated by investigator</description>
    <arm_group_label>Placebo and Basic treatment</arm_group_label>
    <other_name>Placebo for Jaktinib Dihydrochloride Monohydrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent signed;at least 50 years of age;no gender limitation.

          2. Diagnosed idiopathic pulmonary fibrosis(see 2018.9 guidance that AST and ERS and JRS
             and ALAT publish );

          3. FVC%≥45% normal predicted value;

          4. DLCO≥30% normal predicted value；

          5. FEV1 / FVC ≥0.7

        Exclusion Criteria:

          1. A plan of lung transplant after into group for one year.

          2. In addition of IPF,Other causes cause interstitial lung disease in patients；

          3. Patients with bleeding tendency (INR &gt; 2, PT or APTT &gt; 1.5 times normal) or cerebral
             hemorrhage in the past 1 year;

          4. Have used anticoagulant drugs within 1 month（Except for low molecular weight heparin）;

          5. An alcoholic or drug abuser;

          6. Expected survival ≤ one year;

          7. Patients who plan to undergo a operation within study period, such as major operations
             on chest and abdomen;

          8. Previous use of a JAK inhibitor for more than 10 days or treatment failure;

          9. Suspected allergic to Jaktinib Dihydrochloride Monohydrate , similar drugs
             (Fedratinib,Ruxolitinib)or their excipients;

         10. Patients with malignant tumors in the previous 5 years;

         11. Patients with other serious diseases that investigators believe may affect patient
             safety or compliance;

         12. Any significant clinical or laboratory abnormalities that the investigator considers
             to affect safety assessment, such as: a. uncontrolled diabetes (13.9 tendency &gt; / L),
             b. had high blood pressure and antihypertensive drug treatment under two or unable to
             descend to the ranges (systolic blood pressure &lt; 160 mmHg, diastolic pressure &lt; 100
             mmHg), c. peripheral neuropathy (NCI - CTC AE v5.0 standard grade 2 or above)；

         13. Patients hospitalized for deterioration or acute exacerbation of IPF within 1 month
             prior to screening;

         14. patients who had not fully recovered from surgery within 1 month prior to screening;

         15. Participate in clinical trials of other new drugs or medical devices within 3 months
             before screening;

         16. Prednisone &gt; 15mg/ day or equivalent within 1 month prior to screening;

         17. Those who had used pirfenidone, nidanib, azathioprine, cyclophosphamide, cyclosporine
             A or other immunosuppressive drugs within 1 month prior to screening;

         18. A history of congestive heart failure, uncontrolled or unstable angina or myocardial
             infarction, cerebrovascular accident or pulmonary embolism occurred within 6 month
             prior to screening;

         19. Patients with active TB in the 12 months prior to screening;

         20. Screening patients with arrhythmia requiring treatment, or with QTcB &gt;480ms;

         21. At the time of screening, there was evidence of severe impairment of organ function :
             including ALT and AST &gt; 2.5uln;DBIL and TBIL &gt; 2.0 ULN;Serum creatinine &gt; was 1.5 ULN.

         22. Evidence of active and uncontrolled viral infections such as HIV, HBV (HBsAg positive,
             hbv-dna positive or ≥10000 copies /ml), HCV (anti-hcv antibody or hcv-rna positive),
             or bacterial, viral, parasitic or fungal infections requiring treatment with any
             clinical symptoms;

         23. patients with a history of progressive multifocal leukoencephalopathy in Screening ;

         24. Patients with epilepsy or using antipsychotics(Sleep medicine,for diazepam expect) for
             treatment of mental illness( schizophrenia,depressed,mania,anxiety,and so on) at the
             time of screening;

         25. Women who are planning to become pregnant or who are pregnant or breast-feeding and
             who are unable to use effective contraception throughout the trial period;Male
             patients who did not use condoms during administration and within 1 month after the
             last dose;

         26. Subjects who cannot be treated and followed up according to the protocol;

         27. Any subject whom the investigator considers inappropriate for this clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xu Zuo Jun</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xu Zuo Jun</last_name>
    <phone>13671345136</phone>
    <email>xuzj@hotmail.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2020</study_first_posted>
  <last_update_submitted>July 26, 2020</last_update_submitted>
  <last_update_submitted_qc>July 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

